Bellicum reports fourth quarter 2021 financial results and provides operational update

- confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mcrpc) patients treated with bpx-601 in phase 1/2 study -

BLCM Ratings Summary

BLCM Quant Ranking